Document is current
Any future updates will be listed below
-
Authors
Parker, William A. E. https://orcid.org/0000-0002-7822-8852
Sagar, Rebecca
Kurdee, Zeyad
Hawkins, Fladia
Naseem, Khalid M.
Grant, Peter J.
Storey, Robert F.
Ajjan, Ramzi A. https://orcid.org/0000-0002-1636-3725
-
Clinical Trials BETA
Clinical trials referenced in this document:
2008-007875-26 at EU Clinical Trials RegisterDocuments that mention this clinical trial
-
Funding
Funding for this research was provided by:
British Heart Foundation (British Heart Foundation)
- License Information
-
More Information
Article History
Received: 14 October 2021
Accepted: 4 December 2021
First Online: 17 December 2021
Declarations
:
: This trial was approved by the National Health Service Research Ethics Service prior to commencement.
: Not applicable.
: RF Storey reports institutional research grants/support from AstraZeneca, Cytosorbents and GlyCardial Diagnostics; consultancy fees from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, CSL Behring, Cytosorbents, GlyCardial Diagnostics, Hengrui, Idorsia, Novartis, PhaseBio, Portola, Sanofi Aventis and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb/Pfizer, Intas Pharmaceuticals and Medscape. RA. Ajjan. received honoraria and educational and research support from Abbott Diabetes Care, AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, Sanofi, MSD, and Boehringer Ingelheim. The other authors report no relevant disclosures.
